Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis

Abstract

Objective Targeting HER2 has significantly improved Overall Survival (OS) for breast cancer (BC) patients. Trastuzumab, a pivotal first-line BC drug, has transformed patient outcomes, and the introduction of trastuzumab deruxtecan (T-DXd) has provided an additional source of hope for patients with BC. The aim of this meta-analysis is to comprehensively appraise the clinical effectiveness and safety aspects of T-DXd in patients with BC. Methods Electronic databases, including PubMed, Web of Science, Embase, and Cochrane Library, were methodically searched until April 6, 2023. Data analysis was performed using Stata 15.0. Result In total, 12 studies were encompassed, consisting of 3 randomized controlled trials (RCTs) providing data and 9 single-arm studies. In the RCTs, T-DXd were shown to OS[ES = 0.62, 95%CI (0.52,0.75); P = 0.826]、PFS[ES = 0.36, 95%CI (0.25,0.51); P = 0.003]、ORR[RR = 2.46,95%CI(2.18,2.78); P = 0.166], compared with Control group, in patients assigned to T-DXd show better outcomes. For single-arm studies, after T-DXd therapy, patients with breast cancer achieved an ORR[ES = 0.57, 95%CI (0.50–0.64)], DCR[ES = 0.94, 95%CI (0.91–0.97)]. Conclusion T-DXd exhibits promising application prospects for breast cancer patients. However, further clinical trials and foundational research are imperative to robustly substantiate our findings.